Perimenopause rarely announces itself. It slips in through the side door instead. Your period comes early one month. Then it skips two. Sleep turns thin and useless. Your patience runs out for no clear reason. Your jeans fit like they belong to someone else. Meanwhile your doctor checks your thyroid and says you look fine.
Millions of women live in that fog for years. But a lot changed over the past year. The FDA rewrote the warning labels on hormone drugs. A new pill reached pharmacy shelves. Doctors got fresh guidance on how to spot the change early. Employers started paying attention as well. So here is what is happening in your body, and what is new.
What Perimenopause Actually Is
Menopause is one day on the calendar. It is the day you hit twelve months with no period. The years leading up to it are perimenopause. That stretch can run for a decade.
Your ovaries do not wind down in a smooth line. Estrogen spikes, then it crashes. Because of those swings, symptoms often feel worse before your periods stop. In other words, the hardest part usually comes first.
Most women spend about four years here. Some pass through in a few months, while others take eight years or more.
The European Society of Endocrinology set a clear rule in October 2025. Doctors should suspect perimenopause when your cycle runs shorter than 21 days or longer than 35. They should also suspect it in women aged 40 to 45 with hot flashes or odd bleeding. The Endocrine Society in the United States backed the guideline. So did menopause groups in Europe and Britain.
Under 40, the rules change. Then doctors look for premature ovarian insufficiency, which affects roughly 1 to 3 percent of women.
Perimenopause at a Glance
Typical start: Mid to late 40s, sometimes the late 30s
Average length: About four years, though it can run eight years or longer
Median age of menopause in the U.S.: 51 to 52
Hot flashes: Close to 80 percent of women get them
Blood test after 45: Not needed to make the diagnosis
Why Perimenopause Gets Missed So Often
Here is the frustrating part. Perimenopause lands in the busiest decade of a woman’s life. You may be running a team, raising kids, caring for parents, and holding a house together. So the symptoms get filed under stress.
Doctors miss it too. Researchers writing in the British Journal of General Practice talked with women aged 45 to 55. Each one had raised a mental health problem with her family doctor. Many never linked their mood to hormones. Several felt too awkward to bring it up. The doctors, for their part, admitted gaps in their own training. Short visits made the conversation harder still.
The result is easy to guess. A woman leaves with an antidepressant when hormones were the likely driver. That does not make antidepressants wrong for everyone. Still, the pattern costs women years.
Ask your clinician straight out whether hormones could explain your symptoms. That one question often turns the whole visit around.
The Symptom List Is Much Longer Than Hot Flashes
Pop culture shrank this change into a single image. A woman fans herself at a dinner table. Real life looks nothing like that.
Hot flashes and night sweats do lead the list. Close to 80 percent of women get them, according to a February 2026 editorial in American Family Physician. About half of them get flashes daily. For many women, they last seven to ten years.
But the rest of the list gets ignored. Watch for these:
- Broken sleep with no hot flash to blame
- Brain fog and words that vanish mid-sentence
- New anxiety or low mood, often with no history of either
- Aching joints and stiff mornings
- Vaginal dryness, painful sex, repeat urinary infections, and sudden urgency
- Heavy or wildly unpredictable bleeding
- A racing heart and a much shorter fuse
Vaginal and bladder symptoms deserve their own note. Hot flashes fade with time. These do not. Instead they get worse without treatment. Low-dose vaginal estrogen treats them well, and very little of it reaches the bloodstream.
How Doctors Should Diagnose Perimenopause Now
Plenty of women get sent for hormone blood work. Often the result tells you nothing. Estrogen and FSH swing wildly during perimenopause. One blood draw catches one random moment.
Current guidance says so plainly. Women over 45 with typical symptoms do not need blood tests for a diagnosis. Your symptom history and your cycle pattern are enough. British guidance from NICE says the same for healthy women aged 45 and up.
Tests still help in some cases. Under 40, hormone levels confirm premature ovarian insufficiency. Between 40 and 45, an FSH test can add useful information. Certain drugs and a hormonal IUD also blur the picture.
Before you start hormone therapy, the 2025 guideline asks for two checks. Your doctor should weigh your fracture risk and your heart risk. That step helps pick the safest option for you.
The FDA Rewrote the Hormone Therapy Rules
Every estrogen product carried a boxed warning for 23 years. That black box grew out of the Women’s Health Initiative results in the early 2000s. Prescriptions fell off a cliff afterward. A whole generation got steered away from treatment.
Then the FDA reversed course on November 10, 2025. It asked drug makers to strip the boxed warning from estrogen products for menopause. Heart disease and breast cancer language comes out of the box. Wording about probable dementia comes out as well. Those risks still appear in the label, just outside the box. One boxed warning stays, and it covers cancer of the uterine lining with estrogen-only products.
“Women and their physicians should make decisions based on data, not fear.” FDA Commissioner Marty Makary
The new labels also add language about timing. Women who start within ten years of menopause, usually before 60, tend to fare better than women who start later.
Do not read that as a green light for everyone. Jessica Chan, a hormone specialist at Cedars-Sinai, put it plainly. Dropping the box lowers a barrier to care. It does not make hormone therapy right for every woman. A history of blood clots or a hormone-driven cancer still changes the math. Social media took a victory lap that the science does not fully support.
Nonhormonal Options Finally Arrived
Some women cannot take estrogen. Others simply do not want it. Their choices used to be thin.
A new drug class changed that. These pills act on the brain’s heat control center. Fezolinetant, sold as Veozah, came first in 2023. Then the FDA approved elinzanetant on October 24, 2025. Bayer sells it as Lynkuet. It blocks two brain receptors rather than one, and you take one capsule at bedtime. In trials, hot flashes eased within weeks.
| Option | Best For | Worth Knowing |
|---|---|---|
| Systemic hormone therapy | Hot flashes, night sweats, sleep, and bone loss | Boxed warnings removed in 2025 |
| Low-dose vaginal estrogen | Dryness and bladder discomfort | Very little reaches the bloodstream |
| Elinzanetant (Lynkuet) | Moderate to severe hot flashes | Approved October 2025, taken nightly |
| Fezolinetant (Veozah) | Moderate to severe hot flashes | Needs liver enzyme monitoring |
| Menopause-focused CBT | Hot flashes and sleep | Recommended alongside medication |
Both drugs matter for breast cancer survivors, who cannot use estrogen. For years their main options were antidepressants or gabapentin. More drugs are in testing now, including one that works on a different brain pathway.
One caveat belongs here. Most of these trials enrolled women who had already reached menopause, so the evidence for treating perimenopause itself is thinner. Talk through the tradeoffs with a clinician who works in this field.
Perimenopause Does Not Treat Everyone Equally
Most of what medicine knows here comes from one project. SWAN, the Study of Women’s Health Across the Nation, enrolled more than 3,300 women in the mid-1990s. Researchers followed them for over 25 years. Crucially, SWAN included Black, Hispanic, Chinese, and Japanese participants. Earlier menopause research had mostly studied white women.
The findings were stark. Black women reach menopause earlier than white women. They also spend longer in the transition. Hot flashes hit them more often and more severely. Rates of depressed mood run higher too. SWAN found that frequent hot flashes lasted a median of 7.4 years overall, and about a decade in Black women. Hispanic and Latina women tend to start earlier as well.
Adjusting for smoking and weight does not erase the gap. So researchers point to bigger forces instead. Chronic stress from discrimination and money worries both show up in the data. One SWAN analysis looked at everyday discrimination as a direct driver of hot flashes.
Treatment gaps stack on top of that. Researchers reviewed records from nearly 1.9 million women for work presented at a 2026 ACOG meeting. Among white patients, 10.8 percent used hormone therapy. Among Black patients the figure was 5.4 percent. Black patients more often received antidepressants or other alternatives instead.
Perimenopause Is Quietly Costing Women Their Careers
The damage shows up in dollars. Mayo Clinic researchers surveyed 4,440 working women aged 45 to 60. About 13 percent reported a work setback tied to their symptoms. Roughly 11 percent had missed work in the past year.
Those numbers scale fast. The team put the national loss at $1.8 billion in work time each year. Add medical costs and the figure climbs to $26.6 billion. Women with the worst symptoms were over fifteen times likelier to report a work problem than women with the mildest.
An AARP survey put personal spending near $13 billion a year. That covers supplements, prescriptions, copays, and clinic visits. Nine in ten women over 35 reported at least one symptom.
Setbacks go well beyond missed days. Women cut their hours, pass on promotions, retire early, or quit outright. Losing senior women at their peak is a business problem, not just a health one.
How to Get Real Help for Perimenopause
Start by tracking. Log your cycle length, your sleep, your mood, and your symptoms for a couple of months. A clear pattern is much harder to wave away than a vague complaint.
Next, find someone trained in this. The Menopause Society lists certified practitioners by area, and that credential signals real training. Telehealth has widened access as well.
Then bring specific questions. Ask whether your symptoms fit perimenopause. Find out which options suit your own risk profile. Raise vaginal estrogen on its own, since many clinicians forget it. You should also ask what comes next if the first try fails.
Daily habits still count, though nobody should oversell them. Strength training protects bone and muscle. Less alcohol usually means fewer hot flashes and better sleep. Protein at breakfast steadies your energy. Menopause-focused CBT has solid evidence behind it, and it pairs well with medication.
The Bottom Line on Perimenopause
A woman turning 45 today has better information than any generation before her. The labels have been fixed. Two hormone-free drugs now exist where none did five years ago. Guidelines tell doctors to trust symptoms over lab slips. They also tell doctors to take mood changes seriously.
Yet the gap between what medicine knows and what women hear stays wide. Closing it takes patients who ask sharp questions. A shrug is not an answer.
Perimenopause is not a disease. It is not the end of anything either. It is a passage that half the population will make. Treating it with real attention and decent medicine is long overdue.
The information here is general and educational. Talk with a qualified clinician about your own symptoms and treatment options.
